95 related articles for article (PubMed ID: 28717716)
21. The african organization for research and training in cancer.
Holland J
Curr Oncol; 2012 Oct; 19(5):244. PubMed ID: 23144569
[No Abstract] [Full Text] [Related]
22. Pilot Survey of Breast Cancer Management in Sub-Saharan Africa.
Vanderpuye VDNK; Olopade OI; Huo D
J Glob Oncol; 2017 Jun; 3(3):194-200. PubMed ID: 28717760
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
Adelson K; Ramaswamy B; Sparano JA; Christos PJ; Wright JJ; Raptis G; Han G; Villalona-Calero M; Ma CX; Hershman D; Baar J; Klein P; Cigler T; Budd GT; Novik Y; Tan AR; Tannenbaum S; Goel A; Levine E; Shapiro CL; Andreopoulou E; Naughton M; Kalinsky K; Waxman S; Germain D
NPJ Breast Cancer; 2016; 2():16037. PubMed ID: 28721390
[TBL] [Abstract][Full Text] [Related]
24. The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
Wilson TR; Yu J; Lu X; Spoerke JM; Xiao Y; O'Brien C; Savage HM; Huw LY; Zou W; Koeppen H; Forrest WF; Fridlyand J; Fu L; Tam R; Schleifman EB; Sumiyoshi T; Molinero L; Hampton GM; O'Shaughnessy JA; Lackner MR
NPJ Breast Cancer; 2016; 2():16022. PubMed ID: 28721382
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.
Potkul RK; Unger JM; Livingston RB; Crew KD; Wilczynski SP; Salomon CG; Smith BL; Wong L; Campbell DL; Einspahr DE; Anderson GL; Hershman D; Goodman GE; Brown PH; Meyskens FL; Albain KS
NPJ Breast Cancer; 2016; 2():16024. PubMed ID: 28721383
[TBL] [Abstract][Full Text] [Related]
26. Learning from big data: are we undertreating older women with high-risk breast cancer?
Sparano JA; Muss H
NPJ Breast Cancer; 2016; 2():16019. PubMed ID: 28721380
[No Abstract] [Full Text] [Related]
27. Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System.
Debiasi M; Reinert T; Kaliks R; Amorim G; Caleffi M; Sampaio C; Fernandes GDS; Barrios CH
J Glob Oncol; 2017 Jun; 3(3):201-207. PubMed ID: 28717761
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis.
Chatterjee S; Arun I; Agrawal S; Arunsingh M; Mallick I; Ahmed R
J Glob Oncol; 2017 Apr; 3(2):180-181. PubMed ID: 28717757
[No Abstract] [Full Text] [Related]
29. Second Primary Cancers After Primary Breast Cancer Diagnosis in Israeli Women, 1992 to 2006.
Silverman BG; Lipshitz I; Keinan-Boker L
J Glob Oncol; 2017 Apr; 3(2):135-142. PubMed ID: 28717751
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis.
Sandhu GS; Erqou S; Patterson H; Mathew A
J Glob Oncol; 2016 Dec; 2(6):412-421. PubMed ID: 28717728
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of breast cancer characteristics in young premenopausal and postmenopausal women in Ghana.
Bosompem K; Yorke J; Buckman TA; Brenu SG; Nyantakyi M; Aitpillah FS; Kyei I; Adinku MO; Yorke DA; Obirikorang C; Acheampong E
Sci Rep; 2024 Feb; 14(1):2704. PubMed ID: 38302488
[TBL] [Abstract][Full Text] [Related]
32. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
[TBL] [Abstract][Full Text] [Related]
33. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Olopade OI; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Davis MB; Martin ML; Bargonetti J
bioRxiv; 2023 Jun; ():. PubMed ID: 38076873
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for breast cancer among women in Ekurhuleni Metropolitan Municipality, Gauteng province of South Africa, 2017‒2020: a case-control study.
Mashele SA; Zwane TB; Kuonza L; Muchengeti MM; Motsuku L
Ecancermedicalscience; 2023; 17():1593. PubMed ID: 37799951
[TBL] [Abstract][Full Text] [Related]
35. Young Black Women May be More Likely to Have First Mammogram Cancers: A New Perspective in Breast Cancer Disparities.
Wilkerson AD; Obi M; Ortega C; Sebikali-Potts A; Wei W; Pederson HJ; Al-Hilli Z
Ann Surg Oncol; 2023 May; 30(5):2856-2869. PubMed ID: 36602665
[TBL] [Abstract][Full Text] [Related]
36. African Ancestry-Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent.
Martini R; Delpe P; Chu TR; Arora K; Lord B; Verma A; Bedi D; Karanam B; Elhussin I; Chen Y; Gebregzabher E; Oppong JK; Adjei EK; Jibril Suleiman A; Awuah B; Muleta MB; Abebe E; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Chitale DA; Bensenhaver JM; Nathanson DS; Jackson L; Petersen LF; Proctor E; Stonaker B; Gyan KK; Gibbs LD; Monojlovic Z; Kittles RA; White J; Yates CC; Manne U; Gardner K; Mongan N; Cheng E; Ginter P; Hoda S; Elemento O; Robine N; Sboner A; Carpten JD; Newman L; Davis MB
Cancer Discov; 2022 Nov; 12(11):2530-2551. PubMed ID: 36121736
[TBL] [Abstract][Full Text] [Related]
37. Investigation of triple-negative breast cancer risk alleles in an International African-enriched cohort.
Martini R; Chen Y; Jenkins BD; Elhussin IA; Cheng E; Hoda SA; Ginter PS; Hanover J; Zeidan RB; Oppong JK; Adjei EK; Jibril A; Chitale D; Bensenhaver JM; Awuah B; Bekele M; Abebe E; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Nathansan SD; Jackson L; Jiagge E; Petersen LF; Proctor E; Nikolinakos P; Gyan KK; Yates C; Kittles R; Newman LA; Davis MB
Sci Rep; 2021 Apr; 11(1):9247. PubMed ID: 33927264
[TBL] [Abstract][Full Text] [Related]
38. Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer.
Matossian MD; Giardina AA; Wright MK; Elliott S; Loch MM; Nguyen K; Zea AH; Lau FH; Moroz K; Riker AI; Jones SD; Martin EC; Bunnell BA; Miele L; Collins-Burow BM; Burow ME
Womens Health Rep (New Rochelle); 2020; 1(1):383-392. PubMed ID: 33786503
[TBL] [Abstract][Full Text] [Related]
39. Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.
Davis M; Martini R; Newman L; Elemento O; White J; Verma A; Datta I; Adrianto I; Chen Y; Gardner K; Kim HG; Colomb WD; Eltoum IE; Frost AR; Grizzle WE; Sboner A; Manne U; Yates C
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32414099
[TBL] [Abstract][Full Text] [Related]
40. Outcomes and prognostic factors for women with breast cancer in Malawi.
Youngblood VM; Nyirenda R; Nyasosela R; Zuze T; Yang Y; Kudowa E; Moses A; Kincaid J; Kajombo C; Kampani C; Chimzimu F; Mulenga M; Chilima C; Ellis GK; Seguin R; Chagomerana M; Maine R; Jordan S; Charles A; Lee C; Gopal S; Tomoka T
Cancer Causes Control; 2020 Apr; 31(4):393-402. PubMed ID: 32124187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
